ライフサイエンスコーパス: prolactinoma

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 as only seen in patients with acromegaly and prolactinoma.

2 s, 118 (12%) craniopharyngiomas, and 93 (9%) prolactinomas.

3 roups of pituitary adenomas, except for most prolactinomas.

4 in all groups of pituitary adenomas, except prolactinomas.

5 e detected in nearly all adenomas except for prolactinomas.

6 secretion (30-40%; P < 0.05) in four of six prolactinomas.

7 nction, we examined these receptors in human prolactinomas.

8 Prolactinomas account for 32% to 66% of adenomas and pre

9 These results show ErbB3 expression in human prolactinomas and a novel ErbB3-mediated mechanism for P

10 and, most recently, familial acromegaly and prolactinomas and other tumors caused by mutations in th

11 present the first reported pediatric case of prolactinoma associated with SLE, in a 13-year-old white

12 oming the preferred drug in the treatment of prolactinomas because of higher response rate and less s

13 TR5 exclusively regulates PRL secretion from prolactinoma cells.

14 Thus, hst may directly facilitate prolactinoma development via paracrine or autocrine acti

15 phic hyperplastic response, angiogenesis and prolactinoma development, we propose a previously unknow

16 We have shown previously that human prolactinomas express transforming sequences of the hepa

17 eceptor induced hyperprolactinemia and large prolactinomas in females.

18 For prolactinomas, initial therapy is generally dopamine ago

19 Pharmacological treatment of prolactinomas is mainly based on dopamine agonists.

20 The various histologic types include prolactinomas, nonfunctioning adenomas, somatotropinomas

21 s use, renal failure, hypothyroidism, and by prolactinoma - PRL secreting tumors.

22 ld be useful for the treatment of aggressive prolactinomas resistant to conventional therapy.

23 e control of PRL secretion and tumor load in prolactinomas resistant to dopaminergic treatment, or fo

24 Symptomatic hyperprolactinemia and prolactinomas should be treated to lower PRL levels, dec

25 d not suppress PRL release from six cultured prolactinomas studied.

26 malignant) while the remaining tumour was a prolactinoma; three ectopic secretors of ACTH (two bronc

27 tant to dopaminergic treatment, or for those prolactinomas undergoing rare malignant transformation.

28 The diagnosis of pituitary prolactinoma was based on the histologic features and th

29 pituitary tumours assessed, two (including a prolactinoma) were essentially negative, while the third

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。